We represented a pharmaceutical company in a government investigation into, among other things, alleged illegal off-label marketing of one of its drugs. This investigation is significant because the investigation became public when the fact of its existence (but not the fact that we are representing this company) was disclosed in securities filings with the U.S. Securities Exchange Commission (SEC). To date, no enforcement action has been taken.
Government Investigation of Pharmaceutical Company
You Also May Be Interested In:
Obtained a jury trial victory on six of seven counts for the former vice president of Pilot Flying J who, along with three others, was accused of seeking to defraud customers
Successful representation of a public company in an 18-month Securities & Exchange Commission (SEC) investigation related to accounting and disclosure issues, resulting in a decision by the SEC to terminate the investigation
Represented a large hospital system and negotiated a favorable settlement with HHS-OIG utilizing the OIG’s Self-Disclosure Protocol. More specifically, our team conducted an internal investigation into possible compliance issues, drafted the disclosure for provision to HHS-OIG, and negotiated the final settlement between the parties resulting in a favorable resolution for the hospital.